Alogliptin

Chemical formula: C₁₈H₂₁N₅O₂ Molecular mass: 339.392 g/mol PubChem compound: 11450633

Active ingredient description

Alogliptin is a potent and highly selective inhibitor of DPP-4, >10,000-fold more selective for DPP-4 than other related enzymes including DPP-8 and DPP-9. Alogliptin improves glycaemic control via a glucose-dependent mechanism, whereby insulin release is enhanced and glucagon levels are suppressed when glucose levels are high.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC Group		Classification
A10BH04		A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors
Discover more medicines within A10BH04

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Document	Type	Information Source
VIPIDIA Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)
NESINA Film-coated tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicines

Alogliptin is an active ingredient of these brands:

Australia (AU)

NESINA as ALOGLIPTIN BENZOATE
(combination) NESINA MET

Austria (AT)

VIPIDIA as ALOGLIPTIN BENZOATE
(combination) INCRESYNC
(combination) VIPDOMET

Brazil (BR)

NESINA as ALOGLIPTIN BENZOATE
(combination) NESINA MET
(combination) NESINA PIO as ALOGLIPTIN BENZOATE

Canada (CA)

NESINA as ALOGLIPTIN BENZOATE
(combination) KAZANO as ALOGLIPTIN BENZOATE

Croatia (HR)

VIPIDIA as ALOGLIPTIN BENZOATE
(combination) INCRESYNC
(combination) VIPDOMET

Ecuador (EC)

FEBUDAN as ALOGLIPTIN BENZOATE
(combination) FEBUMET as ALOGLIPTIN BENZOATE

Estonia (EE)

VIPIDIA as ALOGLIPTIN BENZOATE
(combination) INCRESYNC
(combination) VIPDOMET

Finland (FI)

VIPIDIA as ALOGLIPTIN BENZOATE
(combination) INCRESYNC
(combination) VIPDOMET

France (FR)

VIPIDIA as ALOGLIPTIN BENZOATE
(combination) VIPDOMET

Hong Kong (HK)

NESINA as ALOGLIPTIN BENZOATE
(combination) NESINA MET
(combination) OSENI as ALOGLIPTIN BENZOATE

Ireland (IE)

VIPIDIA as ALOGLIPTIN BENZOATE
(combination) INCRESYNC
(combination) VIPDOMET

Italy (IT)

VIPIDIA as ALOGLIPTIN BENZOATE
(combination) INCRESYNC
(combination) VIPDOMET

Japan (JP)

NESINA as ALOGLIPTIN BENZOATE
(combination) INISYNC as ALOGLIPTIN BENZOATE
(combination) LIOVEL as ALOGLIPTIN BENZOATE

Lithuania (LT)

VIPIDIA as ALOGLIPTIN BENZOATE
(combination) INCRESYNC
(combination) VIPDOMET

Mexico (MX)

(combination) INCRESINA P

Poland (PL)

VIPIDIA as ALOGLIPTIN BENZOATE
(combination) INCRESYNC
(combination) VIPDOMET

Singapore (SG)

NESINA as ALOGLIPTIN BENZOATE

Spain (ES)

VIPIDIA as ALOGLIPTIN BENZOATE
(combination) INCRESYNC
(combination) VIPDOMET

Turkey (TR)

VIPIDIA as ALOGLIPTIN BENZOATE

United Kingdom (UK)

VIPIDIA as ALOGLIPTIN BENZOATE
(combination) VIPDOMET

United States (US)

NESINA as ALOGLIPTIN BENZOATE
(combination) KAZANO as ALOGLIPTIN BENZOATE
(combination) OSENI as ALOGLIPTIN BENZOATE

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.

Next: Usage >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.